

GP1648  
ITW

Docket No.  
57155-AA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: **Christophe P.G. Gerald, et al.**

Group Art Unit: **1646**

Application No.: **09/866,248**

Examiner: **Joseph F. Murphy**

Filed: **May 25, 2001**

For: **DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF)  
RECEPTORS AND USES THEREOF**

Date: **October 13, 2004**

**CERTIFICATE OF MAILING**  
**BY "FIRST CLASS MAIL" (37 C.F.R. § 1.8)**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following correspondence:

**Fee Transmittal for FY 2005 (PTO/SB/17); Amendment In Response To September 2, 2004 Office Action and Supplemental Information Disclosure Statement (14 pgs); Information Disclosure Statement by Applicant (PTO/SB/08a) (1pg); Copy of U.S. Serial No. 09/538,036; and Check (\$180.00)**


is being deposited on **October 13, 2004** with the United States Postal Service as first class mail in an envelope bearing sufficient postage thereon and addressed to:

**Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450.**

**Mary Johnson**

(Typed Or Printed Name Of Person Mailing Correspondence)

(Signature Of Person Mailing Correspondence)



OCT 15 2004

PTO/SB/17 (10-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 180.00)

**Complete if Known**

Application Number 09/866,248

Filing Date May 25, 2001

First Named Inventor Christophe P.G. Gerald

Examiner Name J. F. Murphy

Art Unit 1646

Attorney Docket No. 57155-AA

**METHOD OF PAYMENT (check all that apply)**☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit Account Number  
Deposit Account Name

503201

Synaptic Pharmaceutical Corp.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	790	2001	395	Utility filing fee	
1002	350	2002	175	Design filing fee	
1003	550	2003	275	Plant filing fee	
1004	790	2004	395	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$ 0.00)

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>	<input type="text" value="0"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X	<input type="text"/>	<input type="text" value="0"/>
Multiple Dependent					<input type="text"/>	<input type="text"/>

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	88	2201	44	Independent claims in excess of 3	
1203	300	2203	150	Multiple dependent claim, if not paid	
1204	88	2204	44	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$ 0.00)

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	430	2252	215	Extension for reply within second month	
1253	980	2253	490	Extension for reply within third month	
1254	1,530	2254	765	Extension for reply within fourth month	
1255	2,080	2255	1,040	Extension for reply within fifth month	
1401	340	2401	170	Notice of Appeal	
1402	340	2402	170	Filing a brief in support of an appeal	
1403	300	2403	150	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,370	2501	685	Utility issue fee (or reissue)	
1502	490	2502	245	Design issue fee	
1503	660	2503	330	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)

**SUBMITTED BY**

(Complete (if applicable))

Name (Print/Type)

Stephen G. Kalinchak

Registration No.  
(Attorney/Agent)

38,747

Telephone (201) 261-1331

Signature

Date

October 13, 2004

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Dkt. 57155-AA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Christophe P.G. Gerald, et al.  
Serial No.: 09/866,248 Examiner: J. F. Murphy  
Filed: May 25, 2001 Group Art Unit: 1646  
For: DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF)  
RECEPTORS AND USES THEREOF

215 College Road  
Paramus, New Jersey  
October 13, 2004

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT IN RESPONSE TO SEPTEMBER 2, 2004 OFFICE ACTION AND  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

This Amendment is submitted in response to the September 2, 2004 Office Action issued in connection with the above-identified application. A response to the September 2, 2004 Office Action is due December 2, 2004. Accordingly, this Amendment is being timely filed.

In response to the September 2, 2004 Office Action, please amend the subject application as follows:

**Amendments to the Claims** are reflected in the listing of claims 1-191 which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 12 of this paper.

**Supplemental Information Disclosure Statement** begins on page 13 of this paper.